Overall, our study assessed the ability of OCT4+CTC to predict treatment response and survival in advanced CCA patients who received ICI treatment, which showed that OCT4+CTC had potential prognostic values in these patients. This evidence concerns the gene POU5F1 and cholangiocarcinoma.